JP6959942B2 - タンパク質生成のための脂質代謝のモジュレーション - Google Patents

タンパク質生成のための脂質代謝のモジュレーション Download PDF

Info

Publication number
JP6959942B2
JP6959942B2 JP2018557851A JP2018557851A JP6959942B2 JP 6959942 B2 JP6959942 B2 JP 6959942B2 JP 2018557851 A JP2018557851 A JP 2018557851A JP 2018557851 A JP2018557851 A JP 2018557851A JP 6959942 B2 JP6959942 B2 JP 6959942B2
Authority
JP
Japan
Prior art keywords
cell
lmm
cells
nucleic acid
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018557851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514399A (ja
JP2019514399A5 (enExample
Inventor
バッジ、ジェームズ
マーク スメールズ、クリストファー
ナイト、タンヤ
ヤング、ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Publication of JP2019514399A publication Critical patent/JP2019514399A/ja
Publication of JP2019514399A5 publication Critical patent/JP2019514399A5/ja
Application granted granted Critical
Publication of JP6959942B2 publication Critical patent/JP6959942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0097—Oxidoreductases (1.) acting on reduced flavodoxin as donor (1.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018557851A 2016-05-03 2017-05-03 タンパク質生成のための脂質代謝のモジュレーション Active JP6959942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330973P 2016-05-03 2016-05-03
US62/330,973 2016-05-03
PCT/EP2017/060484 WO2017191165A1 (en) 2016-05-03 2017-05-03 Modulation of lipid metabolism for protein production

Publications (3)

Publication Number Publication Date
JP2019514399A JP2019514399A (ja) 2019-06-06
JP2019514399A5 JP2019514399A5 (enExample) 2020-06-18
JP6959942B2 true JP6959942B2 (ja) 2021-11-05

Family

ID=58745198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557851A Active JP6959942B2 (ja) 2016-05-03 2017-05-03 タンパク質生成のための脂質代謝のモジュレーション

Country Status (13)

Country Link
US (3) US10655111B2 (enExample)
EP (1) EP3452608B1 (enExample)
JP (1) JP6959942B2 (enExample)
KR (1) KR102536221B1 (enExample)
CN (1) CN109415748A (enExample)
AU (1) AU2017259010B2 (enExample)
CA (1) CA3023038C (enExample)
EA (1) EA201892503A1 (enExample)
ES (1) ES2938626T3 (enExample)
IL (2) IL294241B2 (enExample)
MX (1) MX2018013499A (enExample)
SG (1) SG11201809626PA (enExample)
WO (1) WO2017191165A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6959942B2 (ja) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション
WO2020014483A1 (en) * 2018-07-11 2020-01-16 Cornell University Supported plant plasma membrane lipid bilayer on-a-chip
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020084528A1 (en) * 2018-10-24 2020-04-30 Selexis Sa Expression systems, recombinant cells and uses thereof
US11504390B2 (en) 2019-03-20 2022-11-22 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
CN110317799A (zh) * 2019-07-18 2019-10-11 江南大学 一种人源岩藻糖转移酶8的原核表达方法及其产品
KR20220097910A (ko) 2019-11-14 2022-07-08 론자 리미티드 세포 선택 방법
CN115029307A (zh) * 2022-07-28 2022-09-09 吉林大学 一种延缓MSCs衰老的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
WO2002095008A2 (en) * 2001-02-02 2002-11-28 Bayer Corporation Methods of modulating surfactant phospholipid production
AU2004248165A1 (en) * 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
CN102286483B (zh) 2004-04-16 2014-06-04 中化帝斯曼制药有限公司荷兰公司 用于在真菌细胞中表达基因的真菌启动子
CA2606576A1 (en) * 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
US20080182249A1 (en) * 2006-09-01 2008-07-31 Fox Brian G Expression systems for mammalian and mycobacterial desaturases
US20110281301A1 (en) * 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
CA3015426C (en) * 2008-11-18 2020-01-14 Commonwealth Scientific And Industrial Research Organisation Recombinant cells comprising exogenous .delta.5 and .delta.6 desaturases, .delta.5 and .delta.6 elongases, and .delta.4 desaturases
ES2717175T3 (es) * 2013-02-01 2019-06-19 Selexis Sa Expresión mejorada de transgenes y procesamiento
CN105849265B (zh) * 2013-08-06 2021-03-26 英国龙沙生物医药股份有限公司 用于产生供生产重组蛋白的哺乳动物生产细胞的物品和方法
JP6959942B2 (ja) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション

Also Published As

Publication number Publication date
BR112018072434A2 (pt) 2019-02-19
JP2019514399A (ja) 2019-06-06
US20200231944A1 (en) 2020-07-23
KR20190003651A (ko) 2019-01-09
US10655111B2 (en) 2020-05-19
CA3023038C (en) 2023-03-14
IL262646B (en) 2022-08-01
EP3452608A1 (en) 2019-03-13
WO2017191165A1 (en) 2017-11-09
CN109415748A (zh) 2019-03-01
IL294241A (en) 2022-08-01
IL294241B2 (en) 2023-10-01
ES2938626T3 (es) 2023-04-13
US11434474B2 (en) 2022-09-06
IL294241B1 (en) 2023-06-01
AU2017259010A1 (en) 2018-11-22
MX2018013499A (es) 2019-09-11
IL262646A (en) 2018-12-31
SG11201809626PA (en) 2018-11-29
EP3452608B1 (en) 2022-11-30
CA3023038A1 (en) 2017-11-09
US20230047838A1 (en) 2023-02-16
AU2017259010B2 (en) 2021-04-22
US20170321194A1 (en) 2017-11-09
KR102536221B1 (ko) 2023-05-23
EA201892503A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
JP6959942B2 (ja) タンパク質生成のための脂質代謝のモジュレーション
JP5467415B2 (ja) タンパク質製造の改良
KR20210131991A (ko) 구획-특이적 카고 전달을 위한 조성물 및 방법
KR20200108275A (ko) 면역-종양학 및 항-염증 요법을 위한 엑소좀
US20250206805A1 (en) Combination Therapy with Gold Controlled Transgenes
JP2021513849A (ja) 膜タンパク質送達のための組成物および方法
JP2021511781A (ja) 細胞選択方法及び細胞代謝改変方法
JP7049253B2 (ja) 産生改善のためのタンパク質分解の阻害
KR20170133327A (ko) 포유류 세포에서 재조합 단백질 생산을 위한 비타민 및 비타민 대사 유전자 및 단백질의 용도
US20230028899A1 (en) Mercury Controlled Gene Expression
He et al. Mammalian actin‐binding protein 1/HIP‐55 is essential for the scission of clathrin‐coated pits by regulating dynamin‐actin interaction
Xiang et al. Molecular mechanisms controlling the multistage post-translational processing of endogenous Nrf1α/TCF11 proteins to yield distinct proteoforms within the coupled positive and negative feedback circuits
BR112018072434B1 (pt) Método para produzir um polipeptídeo recombinante em uma célula
US20220233638A1 (en) Cell competition inhibitor
Turotszy The role of NARF and other novel progeria-associated genes/proteins in ageing processes.
Boháčová Proximity proteome of intramembrane serine protease RHBDL4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211008

R150 Certificate of patent or registration of utility model

Ref document number: 6959942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250